IR@PKUHSC  > 北京大学公共卫生学院
学科主题公共卫生
Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population
Tian, Jun1; Qin, Xueying1; Fang, Kai1; Chen, Qing2; Hou, Jing3,4; Li, Juan5; Yu, Wenzhen3,4; Chen, Dafang1; Hu, Yonghua1; Li, Xiaoxin3,4
关键词Arms2 Bevacizumab Cfh Htra1 Neovascular Age-related Macular Degeneration Pharmacogenetics
刊名PHARMACOGENOMICS
2012-05-01
DOI10.2217/PGS.12.53
13期:7页:779-787
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Pharmacology & Pharmacy
资助者Ministry of Science and Technology of the People&prime ; s Republic of China, Beijing, China ; Ministry of Science and Technology of the People&prime ; s Republic of China, Beijing, China
研究领域[WOS]Pharmacology & Pharmacy
关键词[WOS]COMPLEMENT FACTOR-H ; ENDOTHELIAL GROWTH-FACTOR ; HTRA1 PROMOTER POLYMORPHISM ; INTRAVITREAL BEVACIZUMAB ; RISK ; RANIBIZUMAB ; VARIANT ; MULTICENTER ; SERPING1 ; SMOKING
英文摘要

Aims: To determine whether there is an association between CFH, ARMS2, HTRA1, VEGF, SERPING1 or C3 genotypes and patient response to treatment with intravitreal bevacizumab for neovascular age-related macular degeneration (AMD). Materials & methods: This was a multicenter prospective study. One hundred and forty four patients with neovascular AMD treated with bevacizumab were recruited from 13 centers. Twelve SNPs were genotyped using Sequenom. Visual acuity score (VAS), central retinal thickness and maximum thickness of lesion were measured at each visit. Results: For the CFH rs800292 polymorphism, mean VAS changes were 4.4, 8.7 and 15.5 letters in the CC, CT and TT genotype carriers (p = 0.009). For ARMS2 rs10490924, mean VAS changes were 3.6, 12.1 and 9.6 letters for the TT, TG and GG genotypes (p = 0.001). For HTRA1 rs11200638, mean VAS changes were 3.6, 12.3 and 9.6 letters for the AA, AG and GG genotypes (p < 0.001). Conclusion: CFH, ARMS2 and HTRA1 genotypes may influence patient response to treatment with intravitreal bevacizumab for neovascular AMD.

语种英语
所属项目编号2006BAI02B05
资助者Ministry of Science and Technology of the People&prime ; s Republic of China, Beijing, China ; Ministry of Science and Technology of the People&prime ; s Republic of China, Beijing, China
WOS记录号WOS:000303694800015
Citation statistics
Cited Times:23[WOS]   [WOS Record]     [Related Records in WOS]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/51444
Collection北京大学公共卫生学院
作者单位1.Minist Educ, Key Lab Vis Loss & Restorat, Beijing, Peoples R China
2.Peking Univ, Hlth Sci Ctr, Sch Publ Hlth, Dept Epidemiol & Biostat, Beijing 100871, Peoples R China
3.Third Mil Med Univ, Prevent Med Coll, Dept Hyg Toxicol, Changqing, Peoples R China
4.Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100871, Peoples R China
5.Beijing Ctr Dis Control & Prevent, Beijing, Peoples R China
Recommended Citation
GB/T 7714
Tian, Jun,Qin, Xueying,Fang, Kai,et al. Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population[J]. PHARMACOGENOMICS,2012,13(7):779-787.
APA Tian, Jun.,Qin, Xueying.,Fang, Kai.,Chen, Qing.,Hou, Jing.,...&Li, Xiaoxin.(2012).Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population.PHARMACOGENOMICS,13(7),779-787.
MLA Tian, Jun,et al."Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population".PHARMACOGENOMICS 13.7(2012):779-787.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Tian, Jun]'s Articles
[Qin, Xueying]'s Articles
[Fang, Kai]'s Articles
百度学术
百度学术Similar articles in
[Tian, Jun]'s Articles
[Qin, Xueying]'s Articles
[Fang, Kai]'s Articles
必应学术
必应学术Similar articles in
[Tian, Jun]'s Articles
[Qin, Xueying]'s Articles
[Fang, Kai]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.